Skip to main content

Table 1 Clinical characteristics at initiation of 7 bDMARDs (bDMARDs-naïve cases)

From: Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study

Variable ABT (n = 390) ADA (n = 374) CZP (n = 135) ETN (n = 616) GLM (n = 208) IFX (n = 650) TCZ (n = 364)
Age (years) 65.5 ± 12.4 55.3 ± 12.8 58.1 ± 16.8 55.5 ± 15.9 62.0 ± 14.8 52.9 ± 13.4 56.6 ± 14.4
Female sex (%) 81.2 79.4 88.8 86.7 86.1 78.0 78.2
Disease duration (years) 9.2 ± 12.4 5.0 ± 7.5 4.7 ± 7.6 8.3 ± 8.7 7.3 ± 10.0 6.9 ± 8.4 7.4 ± 9.4
RF positivity (%) 86.6 73.8 86.2 83.1 75.6 74.2 74.0
ACPA positivity (%) 84.3 75.9 85.7 83.2 73.2 82.9 82.1
DAS28-ESR 4.4 ± 1.2 4.1 ± 1.2 4.6 ± 1.4 4.4 ± 1.4 4.3 ± 1.2 4.5 ± 1.6 4.6 ± 1.5
CDAI 17.7 ± 9.6 14.7 ± 9.1 22.2 ± 12.9 17.3 ± 8.8 17.2 ± 11.5 18.5 ± 12.4 18.1 ± 9.8
HAQ-DI 1.2 ± 0.8 0.7 ± 0.6 1.2 ± 0.8 0.9 ± 0.8 1.1 ± 0.8 1.1 ± 0.9 1.1 ± 0.8
PSL usage (%) 44.2 32.8 44.8 39.2 38.9 36.4 45.7
PSL dose (mg/day) 3.1 ± 7.3 2.9 ± 4.9 1.7 ± 2.6 2.8 ± 3.6 2.3 ± 3.6 3.1 ± 5.9 2.8 ± 3.9
MTX usage (%) 49.1 72.0 76.1 39.4 76.0 100.0 51.2
MTX dose (mg/week) 8.1 ± 2.8 9.4 ± 3.1 9.4 ± 2.9 8.0 ± 2.8 9.2 ± 2.9 8.2 ± 2.5 8.8 ± 3.0
Starting date 2001–2009 (%) 0.0 13.6 0.0 40.4 1.0 60.9 11.5
Starting date 2010–2013 (%) 35.9 53.7 12.6 42.0 40.4 30.2 47.3
Starting date 2014–2019 (%) 64.1 32.7 87.4 17.6 58.7 8.9 41.2
  1. Values are mean ± standard deviation or percentages. bDMARDs biological disease-modifying antirheumatic drugs, ABT abatacept, ADA adalimumab, CZP certolizumab pegol, ETN etanercept, GLM golimumab, IFX infliximab, TCZ tocilizumab, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, DAS28-ESR Disease Activity Score in 28 joints using erythrocyte sedimentation rate, CDAI clinical disease activity index, HAQ-DI Health Assessment Questionnaire disability index, PSL prednisolone, MTX methotrexate